Literature DB >> 12829137

Impact of locoregional radiotherapy in node-positive patients treated by breast-conservative treatment.

André Fortin1, Anne Dagnault, Marie Larochelle, Thi Trinh Thuc Vu.   

Abstract

PURPOSE: The aim of this study is to evaluate the impact of locoregional radiation in node-positive patients treated by tumorectomy and radiation therapy.
METHODS: A retrospective study including all our 1368 T1-2 node-positive patients was conducted. Conservative surgery was followed by breast irradiation. Axillary and supraclavicular irradiation was left to the discretion of the treating radiation oncologist.
RESULTS: In the group receiving locoregional radiation (472 patients), the 10-year regional control was 97% vs. 91% for the group receiving radiation to the breast only (896 patients) (p = 0.004). In a Cox model analysis, locoregional radiation is associated with a better regional control rate (hazard ratio: 0.27; 95% confidence interval: 0.13-0.54, p = 0.0001). Locoregional radiotherapy is associated with a better rate of locoregional control (hazard ratio: 0.56; 95% confidence interval: 0.38-0.8, p = 0.002). In particular, for the N>3 group, the substantial 10-year locoregional failure rate (26% with breast irradiation only) is cut by 50%. Locoregional radiotherapy, however, is not associated with a lower rate of distant metastases.
CONCLUSION: Locoregional radiation decreases the rate of locoregional failure by nearly 50%. Locoregional radiotherapy should be considered for node-positive patients, especially if they have more than 3 positive nodes.

Entities:  

Mesh:

Year:  2003        PMID: 12829137     DOI: 10.1016/s0360-3016(03)00202-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  1 in total

1.  Accelerated partial-breast irradiation (APBI)--ready for prime time?

Authors:  Frederik Wenz; Wilfried Budach; Jürgen Dunst; Petra Feyer; Wulf Haase; Wolfgang Harms; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2009-10       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.